The next generation of beauty: what deserves a closer look

Start with the result you actually want

A beautiful treatment plan starts with a specific goal: soften a frown line, make acne scars less noticeable, improve uneven pigmentation, or restore a little lost volume. Those goals call for different tools. The newest name on a clinic menu is not automatically the best match for your skin, schedule or budget.

Think in terms of one concern, a realistic improvement and an acceptable recovery period. Ask for photographs of patients with a similar concern and skin tone, taken in consistent lighting. A useful consultation should explain what the treatment cannot change as clearly as what it might improve. This guide covers developments worth understanding, rather than a ranking of treatments everyone should try.

Precision resurfacing: match the device to the skin

Fractional lasers treat small columns of skin while leaving surrounding areas untreated. Ablative approaches remove tissue and generally involve more recovery; nonablative approaches work with less surface disruption and usually more subtle results. Depending on the device and settings, clinicians use resurfacing for wrinkles, uneven texture, pigmentation or acne scars. It does not substitute for surgery when the concern is substantial sagging.

A 2026 review in the Journal of the American Academy of Dermatology highlights an essential issue: additional melanin can increase the risk of pigment changes, blistering and scarring with some energy devices. Conservative settings, appropriate device selection and experience treating darker skin matter. The review also notes gaps in large prospective studies in darker skin types. Ask how the proposed protocol has been evaluated for skin like yours.

RF microneedling: an important safety update

Radiofrequency microneedling delivers heat through small electrodes placed into the skin. On October 15, 2025, the FDA warned about reported burns, scarring, fat loss, disfigurement and nerve damage with certain uses. This is a medical procedure for a qualified, trained professional; it is not an at-home treatment.

A September 2026 study examined 86 FDA MAUDE reports associated with these devices from 2020–2025. Fat loss, scarring and persistent redness were prominent reported problems. These reports cannot tell us the complication rate: the database does not count every treatment and reporting is incomplete. They do reinforce the value of asking about depth, settings, anatomy, alternatives and the clinician's complication-management plan.

Standard microneedling and RF microneedling are different procedures. FDA clearance of a device also does not mean the FDA has reviewed combinations with serums, medications or platelet-rich plasma. Ask exactly what will be applied or delivered and whether that combination has supporting evidence.

Collagen stimulators and wrinkle relaxers

Injectables are also becoming more individualized. Poly-L-lactic acid and calcium hydroxylapatite are among the materials used in FDA-approved fillers for particular indications. PLLA results develop gradually, rather than producing an instant finished result. Approval applies to the specific product and use; the label 'biostimulator' is not a blanket endorsement of every treatment area or dilution.

Fillers can cause swelling, lumps or infection. Accidental injection into a blood vessel can cause tissue death, blindness or stroke. Ask whether the chosen product can be reversed, how a vascular emergency would be handled, and what follow-up is included.

Prescription wrinkle relaxers target muscle movement rather than volume. Daxxify is one newer option with FDA evidence for temporary improvement of moderate to severe frown lines. Products are not interchangeable by name or dose. CDC guidance updated in April 2026 emphasizes licensed, trained providers and authentic FDA-approved products. Difficulty breathing or swallowing after an injection requires emergency medical care.

Where exosomes fit today

Exosomes are attracting interest in regenerative skin care, but a plausible biological mechanism does not establish a reliable beauty result. The FDA states that there are no FDA-approved exosome products and has warned about serious adverse events involving unapproved products. A 2025 enforcement letter also addressed exosome products marketed with therapeutic claims.

A cosmetic serum on intact skin, an injection, and a product delivered through recently treated skin are different exposures. Do not treat evidence for one as proof for another. A clinic's use of the word 'regenerative' or 'research' is not evidence that the product has completed an approval process.

Swipe or scroll to compare all columns.